-+ 0.00%
-+ 0.00%
-+ 0.00%

Immunic names Michael Panzara chief medical officer, replacing Andreas Muehler

PUBT·04/28/2026 10:35:14
Listen to the news
Immunic names Michael Panzara chief medical officer, replacing Andreas Muehler
  • Immunic named Michael A. Panzara as chief medical officer, effective April 24, 2026.
  • Panzara will run clinical development, medical affairs, regulatory affairs as Immunic advances vidofludimus calcium through Phase 3 ENSURE trials in relapsing multiple sclerosis.
  • He previously served as chief medical officer at Neurvati Neurosciences, following senior development roles at Wave Life Sciences, Sanofi Genzyme, Biogen.
  • Andreas Muehler stepped down as chief medical officer, remaining with Immunic as a consultant.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2316678_en), on April 28, 2026, and is solely responsible for the information contained therein.